Breaking News

Tweet TWEET

AREVA Med Launches Production of Lead-212 at New Facility

AREVA Med Launches Production of Lead-212 at New Facility

PARIS, Nov. 21, 2013 (GLOBE NEWSWIRE) -- AREVA Med inaugurated today the
Maurice Tubiana Facility located at Bessines-sur-Gartempe, France (Limousin
region). After receiving the administrative authorizations and completing the
prerequisite technical testing, this unique facility has started production to
extract and purify lead-212 for medical use.

This rare metal is used in the development of innovative treatments for
certain cancers that do not respond to other conventional methods. As
innovation in nuclear medicine is dependent upon the availability of high
purity isotopes, the industrial production of the Maurice Tubiana Facility
will provide sufficient amounts of high-purity lead 212 for clinical
development. Lead-212 is being used currently in an AREVA Med Phase 1 clinical
trial at the University of Alabama at Birmingham in the United States.

Patrick Bourdet, CEO of AREVA Med, said: "This facility, completed thanks to
AREVA's expertise in radiochemistry and nuclear facility design and the
support of our partners, confirms AREVA Med's industrial development. This
will allow us to accelerate the development of alpha radio-immunotherapy using
lead-212."

For more information about AREVA Med: http://arevamed.areva.com

MORE ABOUT AREVA MED

AREVA Med is an AREVA subsidiary specializing in the development of innovative
therapies to fight cancer. AREVA Med has developed new processes for producing
high purity lead-212 (^212Pb), a rare metal that is currently at the heart of
promising nuclear medicine research. In 2011, AREVA Med acquired Macrocyclics,
the global leader in high performance chelating agent technology. AREVA Med is
also associated with world-class scientific partners, such as the National
Cancer Institute (NCI), the University of Alabama at Birmingham (UAB), and the
French National Institute of Health and Medical Research (Inserm). In 2012,
AREVA Med and Roche entered a strategic alliance to create novel advanced
alpha radioimmunotherapy treatments to target and kill certain very aggressive
types of cancer cells. For more information: http://arevamed.areva.com/ or
www.targetedtrials.com.

MORE ABOUT AREVA

AREVA supplies advanced technology solutions for power generation with less
carbon. Its expertise and unwavering insistence on safety, security,
transparency and ethics are setting the standard, and its responsible
development is anchored in a process of continuous improvement.

Ranked first in the global nuclear power industry, AREVA's unique integrated
offering to utilities covers every stage of the fuel cycle, nuclear reactor
design and construction, and operating services. The group is actively
developing its activities in renewable energies – wind, bioenergy, solar and
energy storage – to become a European leader in this sector.

With these two major offers, AREVA's 46,000 employees are helping to supply
ever safer, cleaner and more economical energy to the greatest number of
people.

CONTACT: AREVA Med
         Alison Tise
         +1 301  841  1673
         Alison.Tise@areva.com

AREVA Logo